Aurora Cannabis Q4 Earnings Call Highlights
Key takeaways
- Aurora Cannabis Q4 Earnings Call Highlights Aurora Cannabis logo Market Beat Thu, June 11, 2026 at 8:04 PM GMT+7 8 min read ACB Key Points Interested in Aurora Cannabis Inc.?
- Aurora Cannabis beat fiscal 2026 expectations, with net revenue of CAD 321 million, adjusted EBITDA up 32% year over year to CAD 54 million, and a year-end cash balance of CAD 165 million with no debt.
- Fiscal 2027 is expected to be a reset year as Canadian medical reimbursement changes pressure revenue and margins.
Aurora Cannabis Q4 Earnings Call Highlights Aurora Cannabis logo Market Beat Thu, June 11, 2026 at 8:04 PM GMT+7 8 min read ACB Key Points Interested in Aurora Cannabis Inc.? Here are five stocks we like better.
Aurora Cannabis beat fiscal 2026 expectations, with net revenue of CAD 321 million, adjusted EBITDA up 32% year over year to CAD 54 million, and a year-end cash balance of CAD 165 million with no debt. Global medical cannabis was the main growth driver, and more than half of revenue came from outside Canada.
Fiscal 2027 is expected to be a reset year as Canadian medical reimbursement changes pressure revenue and margins. Management said total net revenue and adjusted EBITDA should decline, even though growth in Germany and Poland and the exit from lower-margin businesses should partly offset the hit.